Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage

Life Sci. 2019 Aug 15:231:116538. doi: 10.1016/j.lfs.2019.06.013. Epub 2019 Jun 6.


Apoptosis is a complicated process that involves activation of a series of intracellular signaling. Tissue injuries from diabetes mellitus mostly occur as a consequence of higher rate of apoptosis process due to activation of a series of molecular mechanisms. Several classes of anti-hyperglycaemic agents have been developed which could potentially modulate the apoptotic process resulting in fewer tissue damages. Novel types of anti-hyperglycaemic medications such as sodium glucose cotransporters-2 inhibitors, glucagon like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors have shown to provide potent anti-hyperglycaemic effects, but their influences on diabetes-induced apoptotic injuries is largely unknown. Therefore, in the current study, we reviewed the published data about the possible effects of these anti-hyperglycaemic agents on apoptosis in diabetic milieu as well as in cancer cells.

Keywords: Apoptosis; Cancer; Caspase; DPP-4 inhibitor; Diabetes mellitus; GLP-1 receptor agonist; Oxidative stress; SGLT2 inhibitor.

Publication types

  • Review

MeSH terms

  • Apoptosis / drug effects*
  • Blood Glucose / drug effects
  • Deafness / drug therapy
  • Deafness / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism
  • Dipeptidyl-Peptidase IV Inhibitors / metabolism
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Glucagon-Like Peptides / agonists
  • Humans
  • Hypoglycemic Agents / metabolism*
  • Hypoglycemic Agents / pharmacology*
  • Mitochondrial Diseases / drug therapy
  • Mitochondrial Diseases / metabolism
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology


  • Blood Glucose
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1

Supplementary concepts

  • Noninsulin-dependent diabetes mellitus with deafness